North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.065

-0.9%

Jan 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (260)	1/30/1998 2:15:00 PM
From: Rick Strange	Read Replies (1) of 507

The Dutch vaccine that failed gave immunity chiefly to strains of B. pertussis that carry normal pertactin. This vaccine did not have: pertussis toxoid (PI); filamentous hemagglutinin (FHA) or fimbriae (FIM). In the new strain, a point mutation in its genome has changed one of the amino acids in pertactin, a protein the bacterium carries on its surface. This disguise seems to fool an immune system primed to recognise normal strains of B. pertussis. If a child was vaccinated with a vaccince containing any of the other components listed above, that child would be immunised against this mutant strain. The vaccines used in Britain, France and Finland contain other components in addition to pertactin and that's why they work. The Dutch epidemic was caused because they relied upon the antibody responce to a single component and B. pertussis pulled a "hail Mary" leaving the Dutch in deep Polder.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next